Clinical trials: Busulfan
Leukemia
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00002868
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 744 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than…
- Trial name
- NCT01949129
- Testing
- VP16, TBI, Thiotepa
- Where
- 119 sites in Argentina, Australia and 29 more
- Volunteers
- 1,800 people
- Sponsor
- St. Anna Kinderkrebsforschung
Non-Hodgkin's Lymphoma
Allo-hNHL (FluBuCy)
DSHNHL R3 is a randomized clinical phase II study. The main objective is to estimate the efficacy of rituximab as a prophylactic medication for prevention of graft-versus-host-disease after allogeneic peripheral stem cell…
- Trial name
- NCT00785330
- Testing
- standard GVHD prophylaxis, rituximab
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Leukemia
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002831
- Testing
- Filgrastim, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Leukemia
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases.
- Trial name
- NCT06984536
- Testing
- Reduced ATG plus mini PTCy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Splenomegaly, Myelofibrosis
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.
- Trial name
- NCT06345495
- Testing
- Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial is studying the side effects and how well decitabine works when given as maintenance therapy after standard therapy in treating patients with previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT00416598
- Testing
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 46 sites in United States
- Volunteers
- 546 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
PRO#0118: Decitabine Plus Mini Flu-Bu
This is a single institution study of combining decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation.
- Trial name
- NCT01455506
- Testing
- Decitabine plus Fludarabine and Busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hackensack Meridian Health
Acute Lymphoblastic Leukemia, Adult
Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia
The main purpose of the project is to evaluate the disease free survival and overall survival in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT)…
- Trial name
- NCT03339700
- Testing
- Gemcitabine, Busulfan, Cyclophosphamide
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
ADA-SCID
Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene
The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA…
- Trial name
- NCT01852071
- Testing
- Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of California, Los Angeles
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00301834
- Testing
- alemtuzumab, busulfan, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Hematological Malignancies
Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies
The purpose of this study is to evaluate the engraftment of donor hemopoiesis (proportion of transplanted patients with successful engraftment at day +42) in adult patients affected by high risk hematological malignancies after…
- Trial name
- IBCB (NCT00886522)
- Testing
- Intrabone cord blood infusion
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ewing's Family Tumors, Renal Tumors
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS…
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma
- Trial name
- NCT01505569
- Testing
- Ifosfamide, Etoposide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myeloma
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
The goal of this clinical research study is to learn if the combination of gemcitabine, busulfan, and melphalan, when given before a stem cell transplant, can help to control refractory myeloma.
- Trial name
- NCT01237951
- Testing
- Palifermin, Dexamethasone, Gemcitabine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Leukemia, Myelodysplastic Syndromes
RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT
This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in elderly or high comorbidity burden patients who receive haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
- Trial name
- NCT03412409
- Testing
- Cytarabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Hematologic Malignancies
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
Allogeneic stem cell transplantation is a potentially curative treatment for patients with many hematologic malignancies (e.g. leukemia, lymphoma, and myeloma with high risk of relapse). This process requires a suitable donor.
- Trial name
- NCT01749293
- Testing
- Haploidentical Transplant, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois at Chicago
Hematologic Neoplasms
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
To reduce the number of donors treated with IV AMD3100 who require a second collection to obtain the minimum cells necessary for allogeneic stem cell transplant.
- Trial name
- NCT00914849
- Testing
- AMD3100, Leukopheresis, Stem cell transplant
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine
Hematologic Neoplasms
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
This trial will evaluate the safety and efficacy of post-transplant Cy and sirolimus following reduced intensity allogeneic SCT.
- Trial name
- NCT01244906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northside Hospital, Inc.
Leukemia
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00002549
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 1,520 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC